These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 25113638)
1. Prostaglandin D2-supplemented "functional eicosanoid testing and typing" assay with peripheral blood leukocytes as a new tool in the diagnosis of systemic mast cell activation disease: an explorative diagnostic study. Schäfer D; Dreßen P; Brettner S; Rath NF; Molderings GJ; Jensen K; Ziemann C J Transl Med; 2014 Aug; 12():213. PubMed ID: 25113638 [TBL] [Abstract][Full Text] [Related]
2. Testing and typing of eicosanoid-patterns. Schäfer D J Physiol Pharmacol; 2006 Dec; 57 Suppl 12():47-64. PubMed ID: 17244954 [TBL] [Abstract][Full Text] [Related]
3. Abnormal eicosanoid pattern by blood leukocytes in gastroduodenal ulcer. Baenkler HW; Zeus J; Schenk J; Schäfer D Med Sci Monit; 2004 Oct; 10(10):CR557-62. PubMed ID: 15448594 [TBL] [Abstract][Full Text] [Related]
4. Functional eicosanoid test and typing (FET) in acetylsalicylic acid intolerant patients with urticaria. Velten FW; Bayerl C; Baenkler HW; Schaefer D J Physiol Pharmacol; 2006 Dec; 57 Suppl 12():35-46. PubMed ID: 17244953 [TBL] [Abstract][Full Text] [Related]
5. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. Alvarez-Twose I; González de Olano D; Sánchez-Muñoz L; Matito A; Esteban-López MI; Vega A; Mateo MB; Alonso Díaz de Durana MD; de la Hoz B; Del Pozo Gil MD; Caballero T; Rosado A; Sánchez Matas I; Teodósio C; Jara-Acevedo M; Mollejo M; García-Montero A; Orfao A; Escribano L J Allergy Clin Immunol; 2010 Jun; 125(6):1269-1278.e2. PubMed ID: 20434205 [TBL] [Abstract][Full Text] [Related]
6. Abnormal eicosanoid-pattern of peripheral white-blood cells in gastro-intestinal cancer. Baenkler HW; Schäfer D J Physiol Pharmacol; 2005 Sep; 56 Suppl 5():119-28. PubMed ID: 16247193 [TBL] [Abstract][Full Text] [Related]
7. Characterization and modulation of canine mast cell derived eicosanoids. Lin TY; London CA Vet Immunol Immunopathol; 2010 May; 135(1-2):118-127. PubMed ID: 20036014 [TBL] [Abstract][Full Text] [Related]
9. Familial occurrence of systemic mast cell activation disease. Molderings GJ; Haenisch B; Bogdanow M; Fimmers R; Nöthen MM PLoS One; 2013; 8(9):e76241. PubMed ID: 24098785 [TBL] [Abstract][Full Text] [Related]
10. Implications of prostaglandin D2 and leukotrienes in exhaled breath condensates of asthma. Uchida Y; Soma T; Nakagome K; Kobayashi T; Nagata M Ann Allergy Asthma Immunol; 2019 Jul; 123(1):81-88.e1. PubMed ID: 30986547 [TBL] [Abstract][Full Text] [Related]
11. Biochemical diagnosis of systemic mast cell disorders. Roberts LJ; Oates JA J Invest Dermatol; 1991 Mar; 96(3 Suppl):19S-24S; discussion 24S-25S; 60S-65S. PubMed ID: 16799604 [TBL] [Abstract][Full Text] [Related]
12. A comparative study of eicosanoid concentrations in sputum and urine in patients with aspirin-intolerant asthma. Higashi N; Taniguchi M; Mita H; Osame M; Akiyama K Clin Exp Allergy; 2002 Oct; 32(10):1484-90. PubMed ID: 12372129 [TBL] [Abstract][Full Text] [Related]
13. The effects of anti-asthma drugs on mediator release from cultured human mast cells. Shichijo M; Inagaki N; Nakai N; Kimata M; Nakahata T; Serizawa I; Iikura Y; Saito H; Nagai H Clin Exp Allergy; 1998 Oct; 28(10):1228-36. PubMed ID: 9824389 [TBL] [Abstract][Full Text] [Related]
15. [Eicosanoid metabolism in peripheral blood cells in patients with cystic fibrosis]. Wurm J; Constantinidis J; Bogeschdorfer F; Baenkler H; Böwing B; Iro H HNO; 2001 Nov; 49(11):922-6. PubMed ID: 11759245 [TBL] [Abstract][Full Text] [Related]
16. Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Morrow JD; Parsons WG; Roberts LJ Prostaglandins; 1989 Aug; 38(2):263-74. PubMed ID: 2475889 [TBL] [Abstract][Full Text] [Related]
17. The IgE- and calcium-dependent release of eicosanoids and histamine from human purified cutaneous mast cells. Robinson C; Benyon C; Holgate ST; Church MK J Invest Dermatol; 1989 Sep; 93(3):397-404. PubMed ID: 2504819 [TBL] [Abstract][Full Text] [Related]
18. Effect of prostaglandin E2 on eicosanoid release by human bronchial biopsy specimens from normal and inflamed mucosa. Schäfer D; Lindenthal U; Wagner M; Bölcskei PL; Baenkler HW Thorax; 1996 Sep; 51(9):919-23. PubMed ID: 8984703 [TBL] [Abstract][Full Text] [Related]
19. Detection of the major urinary metabolite of prostaglandin D2 in the circulation: demonstration of elevated levels in patients with disorders of systemic mast cell activation. Awad JA; Morrow JD; Roberts LJ J Allergy Clin Immunol; 1994 May; 93(5):817-24. PubMed ID: 8182221 [TBL] [Abstract][Full Text] [Related]
20. A Practical Guide for Treatment of Pain in Patients with Systemic Mast Cell Activation Disease. Wirz S; Molderings GJ Pain Physician; 2017 Sep; 20(6):E849-E861. PubMed ID: 28934791 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]